From CNBC.: 2024-06-10 17:08:08

Eli Lilly’s Alzheimer’s drug slows disease progression by 29%, could soon be approved by the FDA. This would make the drug the second of its kind after Leqembi from Biogen. The drug targets amyloid plaque in the brain, a hallmark of Alzheimer’s. Studies show the drug to be effective in treating early-stage patients.

The FDA advisory panel unanimously agrees that the benefits of Eli Lilly’s donanemab outweigh its risks, expanding treatment options for the millions diagnosed with Alzheimer’s. The drug showed a 29% slow in progression in patients. Around 24% of trial participants experienced brain swelling with 6% having severe symptoms, while 31% experienced brain bleeding.

Although Eli Lilly’s drug could receive FDA approval, it faces competition from Leqembi as it is less convenient and has more safety liabilities. The drug would require monthly intravenous infusions, whereas Leqembi currently requires bi-weekly infusions and plans to launch an injectable version next year. Experts estimate Eli Lilly’s drug could bring in $500 million in sales by the end of the decade.



Read more at CNBC.: FDA advisors recommend Eli Lilly Alzheimer’s drug donanemab